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Abstract
Background: Venous leg ulcers (VLUs) can take many months to heal and 25% fail to heal. The main treatment for
venous leg ulcers is compression therapy and few additional therapies exist. Two previous trials indicated that low-
dose aspirin may improve healing time, but these trials were insufficiently robust.
Methods: A multi-centred, pilot, phase II, randomised, double blind, parallel-group, placebo-controlled, efficacy trial
(RCT) was conducted to determine: if aspirin improves VLU healing time; the safety of aspirin in this population;
treatment compliance; and the feasibility of recruitment to a phase III trial. We recruited patients from secondary
care who were aged ≥ 18 years, had a chronic VLU and not regularly taking aspirin. Participants were randomly
assigned (1:1) to receive 300 mg of daily aspirin or placebo in addition to standard care, which consisted of multi
component compression therapy aiming to deliver 40 mmHg at the ankle where possible. The randomisation list
was stratified by ulcer size (≤ 5 cm2 or > 5 cm2). The primary endpoint was time to ulcer healing, which was defined
as ‘complete epithelial healing in the absence of scab (eschar) with no dressing required’. Safety outcomes were
assessed in all participants who received at least one dose of the study drug.
Results: Twenty-seven patients were recruited from eight sites (target 100 patients). A short time-frame to recruit
and a large number of patients failing to meet the eligibility criteria were the main barriers to recruitment. There
was no evidence of a difference in time to healing of the reference ulcer following adjustment for log ulcer area
and duration (hazard ratio 0.58, 95% confidence interval 0.18 to 1.85; p = 0.357). One expected serious adverse event
related to aspirin was recorded. A number of options to improve recruitment were explored.
Conclusions: There was no evidence that aspirin was effective in expediting the healing of chronic VLUs. However,
the analysis was underpowered due to the low number of participants recruited. The trial design would require
substantial amendment in order to progress to a phase III (effectiveness) trial.
Trial registration: Clinicaltrials.gov, NCT02333123. Registered on 5 November 2014.
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Background
Chronic venous leg ulcers (VLUs) are open wounds which
can be large and frequently become infected and leak exu-
dates, leading to significant pain and reduction in quality
of life [1, 2]. They are the result of an impaired venous
return related to severe varicose veins, a history of deep
vein thrombosis and trauma or failure of the calf
muscle pump. Other contributing factors are obesity and
immobility [3]. Prevalence of lower limb ulcers increases
with age and is higher in women [4]. It is estimated that
the prevalence of lower limb ulcers is around 1% of the
population [4].
VLUs can take months to heal, have a tendency to
become recurrent (estimated recurrence rates are between
18% and 23%) and approximately 25% fail to heal com-
pletely [1]. UK guidelines recommend the use of compres-
sion bandaging as first-line treatment for VLUs; its aim is
to reduce venous hypertension, improve calf muscle func-
tion and create a wound environment that encourages
healing while reducing maceration and excessive oedema
and moisture. Randomised controlled trials (RCTs) have
shown compression therapy to be effective [5], but healing
can take many months (approximate median healing time
is 12 weeks) [6]. Compression therapy is not always well
tolerated by patients since it can be painful and inconve-
nient; bulky bandages may restrict ankle movement and
cause difficulty in wearing shoes [7]. This may affect com-
pliance to the treatment, which can consequently jeopardise
its effectiveness. Additionally, this treatment can be expen-
sive as, in addition to dressings and bandages, nurse time is
required to change bandages, which can be required weekly
or more frequently.
Some evidence from two small RCTs suggests that
aspirin (300mg/day) may improve VLU healing [8, 9].
Aspirin (acetylsalicylic acid) is inexpensive, readily avail-
able and generally safe to use. Aspirin is a cyclooxygenase
inhibitor that irreversibly reduces prostaglandin and
thromboxane A2 [10]. It is used widely to reduce cardio-
vascular events in those at high risk [11]. The exact me-
chanism by which aspirin may improve time to healing of
VLUs is unclear but is potentially associated with both
inhibition of platelet activation and reduction of inflam-
mation [12, 13]. If aspirin was found to be effective for re-
ducing healing time, with limited risk of treatment-related
harm, it would present a significant reduction in resource
use and improvements in health related quality of life. A
Cochrane review has concluded that it is not possible to
make definitive claims on the risks and benefits of oral
aspirin on the recurrence and healing of VLUs due to the
low quality and insufficient evidence from the two
included RCTs [8, 9]; therefore, further high quality
studies were recommended [12].
The AVURT trial (Aspirin for Venous leg Ulcers
Randomised Trial) was conducted to address the primary
question of whether the addition of 300mg of daily aspirin
to standard evidence-based therapies reduces VLU healing
time. The pilot trial was also developed to assess the feasi-
bility (especially in terms of participant recruitment and
treatment compliance) and safety (in terms of aspirin-
related adverse events) of conducting a larger pragmatic
phase III study, powered to investigate the effectiveness
and cost-effectiveness of aspirin for VLU healing.
Since the trial recruited fewer participants than ex-
pected, the “Results” section focuses mainly on feasibility
aspects, such as adverse events, recurrence and compli-
ance with study capsules. The results from the primary
outcome analysis are also presented. The full results are
reported in the HTA report, which is available on NIHR’s
online Journal Library (https://www.journalslibrary.nihr.
ac.uk/) [14].
Methods
Study design and participants
AVURT was a multi-centred, pilot, phase II, randomised,
double-blind, parallel-group, placebo-controlled, efficacy
trial. Ten recruiting centres participated, which included
leg ulcer hospital outpatient clinics (n = 5), community
leg ulcer clinics or community caseloads (n = 3), a
wounds clinic within a university (n = 1) and a primary
care leg ulcer clinic (n = 1). The full details of the inclu-
sion and exclusion criteria for trial participants can be
found in the study protocol, which has been published
[15]. Briefly, the trial recruited adults (aged 18 years or
over with no upper limit) with at least one chronic VLU,
ulcer area > 1 cm2, ankle branchial pressure index (ABPI)
≥ 0.8 taken within the previous 3 months or, if the ABPI
was incompressible, other forms of clinical assessment to
exclude peripheral arterial disease (e.g. peripheral pulse
examination, toe pressure, duplex ultrasound and clinical
judgement). For patients with more than one ulcer, the
largest ulcer was chosen as the reference ulcer for the
purposes of the trial.
Recruitment
Before approaching patients, study research nurses pre-
screened on three criteria (concomitant aspirin, wound
size and ulcer duration or history of venous ulceration) to
determine those potentially eligible for the study. Two
pre-screening logs were issued. The first, used during the
first 4 months of recruitment, was non-mandatory as
stipulated by the trial Sponsor. The second pre-screening,
implemented in the fifth month of recruitment, was
mandatory in accordance with a recommendation by the
Data Monitoring Committee (DMC). Therefore, the
number pre-screened as shown in the pre-screening
study flow diagram (Fig. 1) is an under-representation
of the number pre-screened as not all sites completed
the non-mandatory log.
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Potentially eligible patients visiting the clinics for a
routine appointment were invited to take part in the trial
by a designated health care professional, including re-
search nurses. A patient information leaflet was provided
and patients were given a minimum of 24 h to consider
participation. A full eligibility check was conducted for
patients who gave consent and an eligibility case report
form (CRF) was completed by the health professional.
Patients were informed during consent that their eligibility
would be subject to confirmation by a doctor. Following
review and confirmation of a patients’ eligibility by a
doctor, the doctor signed off the prescription for the inves-
tigational medicinal product (IMP).
Randomisation and masking
Participants were randomised on a 1:1 basis to receive
either aspirin (300 mg) or placebo, in addition to stand-
ard care. The aspirin and placebo manufacturer, Sharp
Clinical Services UK Limited, generated the randomisa-
tion schedule in advance. The schedule was stratified by
ulcer area (≤ 5 cm2 or > 5 cm2) and mirrored top to
bottom–bottom to top in order to facilitate participant
allocation according to stratification. One randomisation
list was provided to St George’s Hospital Research Phar-
macy and a copy to the Senior Trial Statistician in the
York Trials Unit (YTU). The Research Pharmacy was re-
sponsible for the randomisation, which was performed
upon receipt of a valid prescription for a participant, and
provided the 24-h code-breaking service in case emer-
gency un-blinding was needed. Participants, investigators,
research and treating nurses and other attending clinicians
were unaware of the trial drug allocation throughout
the trial.
Intervention and comparator
Participants in the intervention group were allocated
300 mg of daily oral aspirin (single dose) for 24 weeks
whereas participants in the control group were allocated
daily oral placebo. Placebo capsules were identical in
weight, colour and size to the aspirin capsules and con-
tained the same filler.
Participants were offered an evidence-based standar-
dised approach to the management of their leg ulcers in
accordance with Scottish Intercollegiate Guideline Net-
work (SIGN) guidance [16]. This consisted of multi-
component compression therapy aiming to deliver 40
mmHg of pressure at the ankle, where possible. The type
of dressing used was at the discretion of the healthcare
professionals managing the participants.
Procedure: baseline
After consent and confirmation by a doctor that the
patient was eligible, but prior to randomisation, a nurse
conducted a clinical assessment of the participant and
*The actual number of patients pre-screened was higher since the first version of the Pre-screening log was not 
mandatory. This explains also the reason why the number of consents taken is only 20.
Not approached (n=392)
Taking aspirin (n=110)
Wound 1cm2 (n=78)
Wound duration less than 6 weeks and no 
history of venous ulceration  (n=24)
Non venous/mixed aetiology (n=28)
Prohibited medication (n=76)
Intolerance/contraindication to aspirin (n=11)
Foot ulcer (n=9)
Not expected to be compliant (n=26)
ABPI < 0.8 (n=4)
No ulcer present or already healed (n=28)
Other (n=61)
Did not consent/ineligible 
(n=45)
Ineligible (n=10)
Declined (n=16)
Other disease (n=3)
Not contactable (n=4)
Other reason (n=7)
Not given reason (n=5)
Number of patients pre-screened (n=457)*
Consent taken (n=20)
Approached (n=65)
Approached
Consent
Pre-screening
Fig. 1 AVURT pre-screening study flow
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wound. Baseline demographic and clinical details were re-
corded, including ulcer size, on a paper CRF. Medication
that the patient was currently taking was recorded in a
diary to be retained by the patient.
Procedure: follow-up
Following randomisation, participants continued in the
normal care pathway of weekly or fortnightly clinical as-
sessments at community ulcer clinics, hospital outpatient
clinics or home visits with no additional visits required for
the study. Nurses completed follow-up paper CRFs at each
visit to record assessments of healing outcomes, treatment
concordance with IMP and compression bandaging, AEs
or side effects, change of concomitant medication and
resource use (e.g. number of visits, number of changes to
dressings and changes to compression therapy). Digital
photographs, or leg ulcer tracings, were also taken by the
treating or research nurse at each visit.
Participants kept a medication diary to record any
changes to their concomitant medication. The diary
was reviewed by clinical staff at follow-up visits to
monitor and record changes in medication. Changes
in medication were subsequently reviewed by a doctor
to ensure safety.
All participants were to be followed for 25 weeks.
Procedure: healed ulcers
If the reference ulcer was assessed as healed during the
follow-up period, a photograph was taken and the
participant continued to take the aspirin or placebo for
two further weeks. At this latter time point, they were
re-assessed for healing (as per FDA guidelines on wound
healing [17]). If the ulcer was confirmed as healed at the
reassessment visit, the participant was advised to stop
taking the IMP or placebo and the date of ulcer healing
was recorded as the date the ulcer was first assessed as
healed (i.e. 2 weeks earlier). Participants whose ulcer had
healed no longer continued with regular follow-ups but
were given a card with contact details of the research
nurse at the site and the date of their 25-week follow-up.
Participants were asked to contact the research nurse if
a new ulcer occurred on the reference leg before the end
of the study. If the ulcer was assessed as ‘not healed’ at
the second assessment, the participant was advised to
continue with the trial medication and continued to
receive weekly or fortnightly follow-ups.
Procedure: final follow-up
Final follow-up was 25 weeks post-randomisation. How-
ever, for participants whose leg ulcer was first assessed as
healed in weeks 24–25, follow-up was extended to weeks
26–27, respectively, to allow a 2-week period of assess-
ment to confirm whether the ulcer had healed. For all
participants, no trial medication was taken after week 25.
For participants whose leg ulcer had healed before
week 25, the research nurse or other nursing staff
phoned participants in week 25 to ask if the reference
ulcer had reoccurred and to check for adverse events. At
the end of the study, participants were asked to return
the bottle containing all the remaining capsules in order
to assess compliance. St George’s Research Pharmacy
conducted the pill count.
Outcomes
The primary outcome was time to ulcer healing, which
was defined as ‘complete epithelial healing in the absence
of scab (eschar) with no dressing required’. Time to heal-
ing was measured in days from the date of randomisation
until the first date that healing was recorded. Patients who
did not heal or fully withdrew were censored at the end of
the study or at their last visit, respectively. Secondary out-
comes were: ulcer size (area) measured in cm2 using
image analysis by SigmaScan (Systat Software Inc., San
Jose, CA, USA) and/or wound tracings; recurrence of
reference ulcer; adverse events; ulcer-related pain using a
visual analogue scale; treatment compliance (patient self-
assessment, capsule counting and nurse assessment of
compression concordance); and resource use (i.e. number
of wound consultations and types of dressing used).
Compliance with study capsules was assessed in two
ways. The first was by analysing the answer given to the
question in the CRF, which was completed at each visit:
“How often has the participant taken their AVURT cap-
sules (300mg Aspirin/placebo per day) this week?”.
Numerical values were assigned to the responses available
as follows: every day = 1, most days = 2, some days = 3,
and not at all = 4. To calculate mean level of compliance
with study capsules for each participant, the responses
across all weeks following delivery of the capsules up to
healing/trial exit were summed and divided by the num-
ber of visits attended. This was then categorised as fully
compliant if the mean value was 1, partially compliant if
the value was 2 or 3 and not at all compliant if the value
was equal to 4. The second way of assessing capsule com-
pliance was by the count of returned capsules at the end
of the study. Each participant was given 190 capsules and
by subtracting the number of returned pills it was possible
to obtain an estimate of the number of capsules actually
taken. The number of capsules which should have been
taken was calculated starting from the date of first dose
until 2 weeks after healing (for those who had healed) or
the date of the last visit (for those who did not heal). From
this the percentage of capsules each participant took (of
those they should have taken) was calculated.
Statistical analysis
The target sample size of 100 participants was con-
sidered to be sufficient to demonstrate whether there
Helen et al. Trials          (2019) 20:459 Page 4 of 10
was evidence of an effect of aspirin to treat VLUs. The
primary outcome was time to healing of the reference
ulcer. Assuming a standard error for the hazard ratio
(HR) of 0.105 following adjustment for log area and log
duration of ulcer (as in a previous leg ulcer study with
data on 448 participants, VenUS IV [18]) and applying
this to the smaller sample size of 100 in this study im-
plied that the standard error would be 0.22. A 95% con-
fidence interval (CI) for the log hazard ratio would thus
be log(HR) ± 0.435. Hence, if the hazard ratio for this
study were the same as that suggested by previous
studies (around 1.5 [8, 9]), the CI would be (0.97, 2.31)
which just includes 1.00. It would be unlikely that if the
HR is as suggested in the two previous studies that we
would observe an overall HR below 1.00. Analyses were
conducted using the principles of intention to treat.
Time to healing was summarised using Kaplan-Meier
curves and investigated using a stratified log-rank test.
The primary analysis was a Cox proportional hazard
regression adjusted for ulcer area (cm2) and duration
at baseline, both logarithmically transformed; an un-
adjusted Cox PH regression analysis was also conducted.
Adverse events (AEs) were reported overall and by trial
arm in terms of number of participants with at least one
event, total number of events and number of non-serious
and serious AEs. Differences in total number of events by
trial arm were compared using negative binomial re-
gression adjusted for size and duration of ulcer (both log
transformed). Ulcer recurrence was analysed descriptively
reporting the number of patients who experienced a
recurrence and the time to recurrence from healing.
Compliance with study capsules (self-reported level of
compliance and percentage of capsules taken) were
presented descriptively.
Results
The trial opened to recruitment on 23 June 2015 and
closed to recruitment on 29 February 2016. Participant
follow-up was completed on 18 August 2016. Consent
was obtained from 29 patients but two were excluded
due to health-related problems before randomisation. At
the end of the recruitment period, only 27 patients were
recruited and randomised (Fig. 2): 13 were assigned to
the placebo group and 14 to the aspirin group. Figure 1
presents 20 patients who consented to the trial and who
had pre-screening data. Figure 2 presents the total num-
ber of patients who gave consent (n = 29) and includes
those for whom there was no pre-screening data.
One participant in the placebo group fully withdrew
from the study without having taken any capsules and
therefore no outcome data were collected. Four partici-
pants withdrew from treatment (two placebo, two aspirin)
and either agreed and provided data until the end of
planned follow-up or healed before withdrawal and thus
all four provided primary outcome data. Baseline partici-
pant and ulcer-related characteristics are shown in Table 1.
The average age of the 27 randomised participants was 62
years (SD 13) and two-thirds were male (n = 18). Median
duration of reference ulcer was 15months (range 2–234
Consent taken (n=29)
Excluded for health 
related problems after 
consent was given (n=2)
Analysed (n=12)
Further withdrawals (n=0)
Allocated to Placebo (n=13)
Received Placebo (n=12)
Did not receive Placebo (n=1)
Full withdrawal at week 1, trial 
drug not yet received
Further withdrawals (n=0)
Allocated to Aspirin (n=14)
Received Aspirin (n=14)
Did not receive Aspirin (n=0)
Analysed (n=14)
Allocation
Follow-Up
Randomised (n=27)
Consent
Randomisation
Assessed for eligibility (n=29)
Screening
Analysis
Fig. 2 AVURT CONSORT diagram
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months) and median size of ulcer was 17.1 cm2 (range
2.0–173.0 cm2). All participants were receiving com-
pression therapy at baseline.
A total of 13 participants were recorded as healed
during the course of the study: seven (58.3%) partici-
pants in the placebo group and six (42.9%) in the aspirin
group. All the reference ulcers reported to be healed
were confirmed as such approximately 2 weeks later. It
was not possible to estimate the median time to healing
and/or corresponding 95% CIs where less than 50% of
considered participants healed during the follow-up
period of the study (e.g. in the aspirin group). Therefore,
the 25th percentile of time to healing was also estimated
(Table 2).
Figure 3 shows the Kaplan-Meier plot of proportion of
reference ulcers healed over time by trial arm. The log-
rank test investigating the difference between the sur-
vival curves showed no statistically significant difference
(p = 0.31). Hazard ratios (HRs), corresponding 95% CIs
and p values for the model covariates are reported
in Table 3.
The placebo group tended to heal more rapidly but
this difference is not statistically significant (adjusted HR
0.58 [95% CI 0.18–1.85]). Overall, these data do not
Table 1 Baseline data: participant and ulcer-related characteristics
Placebo (n = 13) Aspirin (n = 14) Overall (n = 27)
Participant characteristic
Age
Mean (SD) 62.1 (15.2) 62.7 (11.6) 62.4 (13.2)
Median (min, max) 66.6 (38.9, 80.8) 59.2 (47.9, 78.9) 62.0 (38.9, 80.8)
Gender, n (%)
Male 7 (53.9) 11 (78.6) 18 (66.7)
Female 6 (46.2) 3 (21.4) 9 (33.3)
BMI
Mean (SD) 32.1 (8.6) 36.6 (15.0) 34.4 (12.3)
Median (min, max) 28.4 (19.9, 44.1) 31.6 (20.9, 70.2) 31.5 (19.9, 70.2)
Ulcer related characteristics
Size of ulcer (cm2)
Mean (SD) 40.7 (55.1) 43.1 (47.6) 42.0 (50.3)
Median (min, max) 16.0 (2.0, 173.0) 31.3 (3.8, 155.0) 17.1 (2.0, 173.0)
≤ 5 cm2, n (%) 3 (23.1) 3 (21.4) 6 (22.2)
> 5 cm2, n (%) 10 (76.9) 11 (78.6) 21 (77.8)
Time since first ulcer (months)
Mean (SD) 112.5 (78.5) 86.4 (86.9) 99.0 (82.4)
Median (min, max) 101.0 (11.0, 240.0) 48 (2.2, 240.0) 72.0 (2.2, 240.0)
Reference ulcer duration (months)
Mean (SD) 58.6 (73.3) 32.2 (52.0) 44.9 (63.3)
Median (min, max) 13.0 (4.0, 234.0) 16.5 (1.8, 192.0) 15.0 (1.8, 234.0)
ABPI
Mean (SD) 1.1 (0.2) 1.0 (0.1) 1.0 (0.2)
Median (min, max) 1.0 (0.8, 1.5) 1.0 (0.9, 1.3) 1.0 (0.8, 1.5)
Table 2 Healing of the reference ulcer (unadjusted analysis)
Placebo (n = 12)* Aspirin (n = 14) Overall (n = 26)
Number healing (n, %) 7/12 (58.3) 6/14 (42.9) 13/26 (50.0)
Kaplan-Meier estimate of median time to healing (days) (95% CI) 98 (21, NE) NE (84, NE) 147 (97, NE)
Kaplan-Meier estimate of 25th percentile time to healing (days) (95% CI) 36 (20, 97) 111 (69, NE) 84 (21, 111)
NE not possible to estimate
*One participant was lost to follow-up immediately after randomisation and provided no outcome data
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provide evidence of a difference in time to healing with
the addition of aspirin to usual care.
Six of the 26 (23.1%) participants followed up had no
reported AEs (three placebo, three aspirin) and the
remaining 20 had at least one AE (nine placebo, 11
aspirin). In total 88 non-serious AEs (36 placebo and 52
aspirin) and one serious AE (“blood transfusion for low
Hb” (haemoglobin); classified as expected and probably
related to aspirin) were registered. There was no evi-
dence from an adjusted negative binomial regression
that participants receiving aspirin were more likely to
suffer an AE than those receiving placebo (incidence rate
ratio 1.31 [95% CI 0.51–3.41], p = 0.58). Among the 13
participants who healed, one recurrence was reported in
each of the treatment groups. The time between ulcer
healing and recurrence was 158 days for the participant
in the placebo group and 126 days for the participant in
the aspirin group.
According to self-assessment of compliance, eight of
the 12 participants (66.7%) in the placebo group were
deemed fully compliant with study capsules while four
(33.3%) were partially compliant. In the aspirin group,
11 of the 14 participants (78.6%) were deemed fully
compliant and three (21.4%) were partially compliant.
Among partially compliant participants, two in the
placebo group and two in the aspirin group were fully
compliant for at least 88% of their visits. Reasons for not
being fully compliant included illness, forgetting to take
the capsule and experiencing an adverse effect. The
other three participants (two placebo, one aspirin) were
deemed to be fully compliant for 54% or less of their
visits. Two of these participants (one aspirin, one
placebo) were withdrawn from treatment at week 8 and
week 14, respectively, while one participant (placebo)
tended to forget to take the capsule. According to the
count of returned capsules, ten participants in the placebo
arm (83.4%) and ten in the aspirin arm (71.5%) took at
least 90% of the study capsules they should have taken.
Barriers to patient recruitment
Several factors contributed to the low recruitment rate
The key factor was that, during recruitment, sites found
fewer than estimated eligible patients. The main reasons
for ineligibility reported in the pre-screening forms were
the current consumption of aspirin or other prohibited
medication, the size of the ulcer (too small) and the type
of ulcer (see flow diagram in Fig. 1). Feedback from sites
suggested that many leg ulcer patients were treated in
primary care settings and in specialist clinics; patients
being seen in the secondary care recruiting sites taking part
in this study were more likely to be older and therefore
already having comorbidities requiring the consump-
tion of aspirin.
Other factors were a 2-month suspension in opening to
recruitment which was due to a delay in the release of the
IMP just prior to recruitment. Once the IMP had been
released, sites were slower than anticipated to open to
recruitment due to limited staff availability over the
summer months and at three sites key staff were on long-
term leave or were waiting for new staff to be in post.
Recruitment strategies considered
In order to improve recruitment, several strategies were
considered. The trial had 6 months initially to recruit
(this was later extended to 8 months) and so it was
necessary to adopt strategies that could be implemented
relatively quickly.
Change to eligibility criteria The only acceptable modifi-
cation to the eligibility criteria was to include a wound
area of less than 1 cm2. This would bring the trial in line
with the concurrent leg ulcer trial in New Zealand [19],
which included small wounds. However, we chose not to
include these in the initial design stage of the trial as these
ulcers tend to heal rapidly. To include patients already
taking aspirin would have resulted in a significant redesign
0.00
0.10
0.20
0.30
0.40
0.50
0.60
0.70
0.80
0.90
1.00
14 14 14 11 8 8 0Aspirin
12 10 9 8 6 5 0Placebo
Numbers at risk
0 30 60 90 120 150 180
Time to healing (days)
Placebo Aspirin
Fig. 3 Kaplan-Meier plot of time to ulcer healing by trial
arm (unadjusted)
Table 3 Healing of the reference ulcer (log-rank test,
unadjusted and adjusted analysis)
Test statistic P value
Log-rank test 1.02 (1df) 0.312
Unadjusted Cox regression
Parameter HR (95% CI) P value
Aspirin vs placebo (allocation) 0.58 (0.19, 1.72) 0.322
Adjusted Cox regression
Parameter HR (95% CI) P value
Aspirin vs placebo (allocation) 0.58 (0.18, 1.85) 0.357
Area (log transformed) 0.42 (0.22, 0.81) 0.009
Duration (log transformed) 0.61 (0.34, 1.08) 0.089
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of the trial, e.g. patients randomised to the intervention
would receive a top-up dose of aspirin to 300mg or
patients randomised to the control group would be asked
to stop taking aspirin. However, this was not considered
feasible for ethical and practical reasons; participants
would be unblinded to treatment and a lower dose IMP
would have been required.
Recruitment from primary care The trial’s DMC sup-
ported a potential new strategy for the trial of recruiting
from primary care. One option was to use GP practices
as recruitment and treatment centres. However, time
and budget constraints related to implementing this
strategy meant that this was not a viable option. Another
option was to use GP practices as patient identification
centres (PICs) who would refer patients to the recruiting
sites; however, preliminary searches of GP practice data-
bases indicated that this too was not a viable option; 14
GP practices in England identified a total of seven
potential patients. In addition a couple of recruiting sites
had waiting lists for their wound service and therefore
would have been unable to take additional referrals from
primary care.
Others Other recruitment strategies considered were
media advertising (on the radio for example), posters for
patients in recruitment sites and allowing more tele-
phone follow-up so that participants who did not visit
clinics as regularly as once a week or fortnightly could
be recruited.
Strategies implemented Flyers to sites to remind clinic
staff to recruit to the trial and three electronic news-
letters to update on recruitment to the trial were imple-
mented since these were relatively cheap to produce and
did not require ethics approval. Sites were also reminded
to identify potential participants before site opening so
that they could be approached as soon as they were
given the green light to recruit.
Discussion
This phase II pilot trial recruited only 27% of its target
sample size but has important findings for informing the
design of future clinical trials of IMPs for this patient
population. There were a number of challenges to
patient recruitment, including a short recruitment win-
dow (initially 6 months, extended to 8months), a delay in
the release of the IMP, staff shortages and absences at
some sites, and many patients not meeting the trial’s
eligibility criteria; for one recruiting site, the usual care
pathway for the majority of VLU patients was for follow-
up treatments to be delivered in the community by nurses
and therefore the site was only able to recruit the few
patients that had follow-up at the site.
There was no statistically significant difference between
the two groups with respect to the proportion of ulcers
that had healed. Ulcers tended to heal more rapidly in the
placebo group but this was not statistically significant.
Due to the low number of participants in the trial (n = 27),
the efficacy of aspirin cannot be confirmed and related
data should be interpreted with caution. However, recent
evidence from another study also found that 300mg of
aspirin is not effective for time to healing of VLUs and,
consistent with our study, although there was no statis-
tically significant significant difference with respect to
healing, the direction of the reported effect favoured the
placebo group [20].
All the registered AEs were non-serious, with the
exception of one serious event. There was no evidence
of a difference in the number of expected AEs in the
two trial arms and aspirin appeared to be generally well
tolerated. Both measures of compliance with trial medi-
cation (self-report and pill count) showed good levels of
compliance. Overall nearly three-quarters of participants
were fully compliant and one-quarter partially com-
pliant. Reasons for not being fully compliant included
forgetting to take the medication, illness and experien-
cing an AE.
Although sites initially indicated that they could recruit,
it became apparent once recruitment was open that a
large proportion of patients seen did not meet the trial’s
criteria. In order to improve recruitment, we explored a
range of options, including recruitment from primary
care, which involved a limited database search of records
held in primary care. Very few patients were identified
(n = 7 patients in 14 GP practices) but there were limi-
tations associated with conducting the search. Further
investigation from primary care was not explored due to
these preliminary findings indicating that recruitment
from primary care might not be effective and due to con-
sideration of the time and budget constraints on the pro-
ject. However, future studies should consider conducting
an audit to identify the number of potential participants.
During the registration of AVURT, we identified two full
scale randomised controlled trials being conducted outside
the UK investigating aspirin for venous leg ulcers [19, 21].
The Aspirin4VLU trial [19], conducted in New Zealand,
investigated low dose aspirin (150mg) and had similar in-
clusion and exclusion criteria, but in contrast had no mini-
mum ulcer size and recruited from a district nursing setting.
The trial was able to recruit 251 participants [20] (Clinical-
Trials.gov, NCT02158806), which suggests that clinical
setting and ulcer size may have been important factors. The
ASPiVLU trial [21] in Australia is currently ongoing.
Limitations
It was estimated that 100 patients were sufficient to de-
monstrate whether there was evidence of an effect of
Helen et al. Trials          (2019) 20:459 Page 8 of 10
aspirin to treat VLUs. As this trial recruited only 27
patients we were unable to determine the effectiveness of
aspirin for this condition.
Generalisability
The majority of the recruiting sites were based in
secondary care. The participants recruited tended to be
aged in their early 60s and have a high BMI score. More
men (n = 67%) than women were recruited. Around a
quarter of patients were excluded because they were
already taking aspirin.
Conclusions
AVURT was a phase II randomised pilot trial of aspirin
versus placebo for the treatment of patients with chronic
VLUs which sought to identify the efficacy of 300 mg of
oral aspirin, feasibility of recruitment, compliance with
treatment and the safety of high dose aspirin in the VLU
patient population. The placebo group tended to heal
more rapidly but this was not statistically significant.
Aspirin appeared to be well tolerated and levels of
compliance were good.
Due to the low number of participants, the efficacy of
aspirin cannot be confirmed and any data should be
interpreted with caution. The trial was not able to
recruit the target number of patients despite a short
unfunded extension to the trial’s recruitment phase and
therefore it was not feasible to proceed to a larger phase
III (effectiveness) trial without significantly changing the
trial design, including eligibility criteria. Key barriers to
recruitment were many patients not meeting the eligibi-
lity criteria and a short recruitment window.
It is recommended that prior to conducting a clinical
trial of an IMP in this patient population, a thorough
audit is carried out to determine the number of potential
patients available for recruitment from secondary or
primary care. The audit should consider the number of
patients already taking the drug being evaluated and
prohibited medication. In order for this pilot trial to pro-
gress to a full scale trial and to successfully recruit from
secondary care without any amendments to the eligibi-
lity criteria, it would need many recruiting centres and
require a long recruitment phase.
The full report for the study is available on NIHR’s on-
line Journals Library (https://www.journalslibrary.nihr.ac.
uk/hta/hta22550/#/full-report).
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